VISTN.OL
Vistin Pharma ASA
Price:  
19.20 
NOK
Volume:  
6,387.00
Norway | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

VISTN.OL WACC - Weighted Average Cost of Capital

The WACC of Vistin Pharma ASA (VISTN.OL) is 5.8%.

The Cost of Equity of Vistin Pharma ASA (VISTN.OL) is 5.90%.
The Cost of Debt of Vistin Pharma ASA (VISTN.OL) is 5.00%.

Range Selected
Cost of equity 5.10% - 6.70% 5.90%
Tax rate 22.00% - 22.00% 22.00%
Cost of debt 5.00% - 5.00% 5.00%
WACC 5.0% - 6.6% 5.8%
WACC

VISTN.OL WACC calculation

Category Low High
Long-term bond rate 3.3% 3.8%
Equity market risk premium 5.1% 6.1%
Adjusted beta 0.35 0.39
Additional risk adjustments 0.0% 0.5%
Cost of equity 5.10% 6.70%
Tax rate 22.00% 22.00%
Debt/Equity ratio 0.06 0.06
Cost of debt 5.00% 5.00%
After-tax WACC 5.0% 6.6%
Selected WACC 5.8%

VISTN.OL's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for VISTN.OL:

cost_of_equity (5.90%) = risk_free_rate (3.55%) + equity_risk_premium (5.60%) * adjusted_beta (0.35) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.